Summary
A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 11/16 (69%), respectively. The complete remission rate for patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) was 10/18 (56%). The treatment-related mortality was 17%. Nine patients whose leukaemia relapsed after matched allogeneic, sibling bone-marrow transplantation (BMT) were also treated in this way; the treatment-related mortality in this group was high (7/9) and the duration of remission in the two patients who responded, too short to justify this intensive treatment in such patients. Similarly, patients who underwent BMT after achieving a complete remission with high-dose Ara-C and etoposide did very poorly, only one patient surviving well and disease-free at 8 months. The important finding in this study was the high complete remission rate rapidly obtained in patients with relapsed or refractory AML without using an anthracycline.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amadori S, Papa G, Avvisati G, Fenu S, Monarca B, Petti MC, Pulsoni A, Mandelli F (1984) Sequential combination of high dose Ara-C (HIDAC) and asparaginase (ASP) for the treatment of advanced acute leukaemia and lymphoma. Leuk Res 8: 729–734
Barnett MJ, Richards MA, Ganesan TS, Waxman JH, Smith BF, Butler MG, Rohatines AZS, Slevin ML, Lister TA (1985) Central nervous system toxicity of high-dose cytosine arabinoside. Semin Oncol 12 (2 Suppl 3): 227–232
Bodey GP, Coltman CA, Freireich EJ, Bonnet JD, Gehan EA, Haut AB, Hewlett JS, McCredit KB, Saiki JH, Wilson HE (1974) Chemotherapy of acute leukaemia—comparison of cytarabine alone and in combination with vincristine, prednisolone and cyclophosphamide. Arch Intern Med 133: 260–266
Cantin G, Brennan JK (1984) High dose cytosine arabinoside for acute non-lymphocytic leukaemia. Am J Hematol 16: 59–66
Capizzi RL, Poole M, Cooper MR, Richards F II, Stuart JJ, Jackson DV Jr, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D (1984) Treatment of poor risk acute leukaemia with sequential high dose Ara-C and asparaginase. Blood 63: 694–700
Carey RW, Ribas-Mundo M, Ellison RR, Glidewell O, Lee ST, Cuttner J, Levy RN, Silver R, Blom J, Haurani F, Spurr CL, Harley JB, Kyle R Moon JH, Eagen RT, Holland JH (1975) Comparative study of cytosine arabinoside therapy alone combined with thioguanine, mercaptopurine or daunorubicin in acute myelocytic leukaemia. Cancer 36: 1560–1566
Cavalli F, Sonntag R, Brunner KW (1975) Epipodophyllotoxin VP16-213 in acute non-lymphoblastic leukaemia. Br Med J 4: 227
Chu MY, Fischer GA (1965) Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14: 333–341
Drewinko B, Ho DHW, Barranco SC (1972) The effects of arabinosyl cytosine on cultured human lymphoma cells. Cancer Res 32: 2737–2742
Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hayes DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchison JL, Forcier RJ, Moon JH (1968) Arabinosyl cytosine: a useful agent in the treatment of acute leukaemia in adults. Blood 32: 507–523
Frei E III, Bicker JN, Hewlett JS, Lane M, Leary WV, Talley RW (1969) Dose schedule and antitumour studies of arabinosyl cytosine (NSC 63878). Cancer Res 29: 1325–1332
Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl Med J 300: 1189–1199
Herzig RH, Herzig GP, Lazarus HM, Wolff SN, Phillips GL (1982) High dose cytosine arabinoside in the treatment of refractory acute non-lymphocytic leukaemia in adults: results of two six day regimens. Med Pediatr Oncol [Suppl] 1: 229–233
Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP (1983) High dose cytosine therapy for refractory leukaemia. Blood 62: 361–369
Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH, (1984) High dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute non-lymphocytic leukaemia. J Clin Oncol 2: 545–549
Hines JD, Mazza JJ, Oken MM, Bennett JM, Adelstein DJ, Keller A, O'Connell MJ (1985) High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukaemia: phase I pilot study for the Eastern Cooperative Oncology Group. Semin Oncol 12: (2 Suppl 3): 117–119
Hwang TL, Yung WK, Estey EH, Fields WS (1985) Central nervous system toxicity of high-dose Ara-C. Neurology 35 (10): 1475–1479
Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of high dose systemic cytosine arabinoside. Cancer 48: 2577–2582
Marcus RE, Catovsky D, Goldman JM, Galton DAG, Newland AC, Slocombe G, Hedge U (1985) Mitozantrone and high dose cytarabine in adult acute myeloid leukaemia. Lancet i: 1384
Momparler RL (1974) A model for the chemotherapy of acute leukaemia with 1-B-d-arabinofuranosyl cytosine. Cancer Res 34: 1775–1787
Momparler RL, Chu MY, Fisher GA (1968) Studies on a new mechanism of resistance of L5178Y murine leukaemia cells to cytosine arabinoside. Biochim Biophys Acta 161: 481–493
Morra E, Lazzarino M, Alessandrino EP, Inverardi D, Canevari A, Bernasconi C (1984) VP16-213 and cytosine arabinoside combination chemotherapy for refractory acute lymphoblastic leukaemia in adults. Eur J Cancer Clin Oncol 20: 1471–1475
Preisler HD, Epstein J, Barcos M, Priore R, Raza A, Browman GP, Vogler R, Winton E, Grunwald H, Rai K, Brennan J, Bennett J, Goldberg J, Gottlieb A, Chervenick P, Joyce R, Miller K, Larson R, D'Arrigo P, Doeblin T, Stein M, Bloom M, Steele R, Lee H (1984) Prediction of response of acute nonlymphocytic leukaemia to therapy with “high dose” cytosine arabinoside. Br J Haematol 58: 19–32
Ritch P, Hansen R, Heuer D (1983) Ocular toxicity from high-dose cytosine arabinoside. Cancer 51: 430–432
Rivera G, Avery T, Roberts D (1975) Response of L1210 to combinations of cytosine arabinoside and VM26 or VP16-213. Eur J Cancer 11:639–647
Rohatiner A, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA (1984) High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 12:90–93
Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S (1979) High dose cytosine arabinoside (HDARAC) in refractory acute leukaemia. Cancer 44: 1189–1193
Rustum YM, Slocum HK, Wang G, Bakshi D, Kelly E, Buscaglia D, Wrzosek C, Early AP, Preisler H (1982) Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high dose Ara-C treatment. Med Pediatr Oncol [Suppl] 1: 33–43
Southwest Oncology Group (1974) Cytarabine for acute leukaemia in adults: effects of schedule on therapeutic response. Arch Intern Med 133:251–259
Wang JJ, Selawry OS, Vietti TJ, Bodey GP (1970) Prolonged infusion of arabinosyl cytosine in childhood leukaemia. Cancer 25: 1–6
Willemze R, Zwaan FE, Colpin G, Keuning JJ (1982) High dose cytosine arabinoside in the management of refractory acute leukaemia. Scand J Haematol 29: 141–146
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gore, M., Powles, R., Lakhani, A. et al. Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother. Pharmacol. 23, 373–376 (1989). https://doi.org/10.1007/BF00435839
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00435839